Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
July 15, 2026 3:30 AM EDTInitiates Global Phase 2 APPlauDS Study of Mivelsiran in Down SyndromeAssociated Alzheimers Disease (DS-AD)
Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA)
Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimers Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA)
Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN5288 in Alzheimers Patients
CAMBRIDGE, Mass.--(BUSINESS... More
